Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.18 EUR
Change Today +0.018 / 11.32%
Volume 0.0
LO9 On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Stuttgart
As of 1:23 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

scivac therapeutics inc (LO9) Snapshot

Open
€0.14
Previous Close
€0.16
Day High
€0.18
Day Low
€0.14
52 Week High
07/13/15 - €0.37
52 Week Low
09/24/14 - €0.09
Market Cap
133.9M
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
756.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SCIVAC THERAPEUTICS INC (LO9)

Related News

No related news articles were found.

scivac therapeutics inc (LO9) Related Businessweek News

No Related Businessweek News Found

scivac therapeutics inc (LO9) Details

Levon Resources Ltd. operates as a precious metal exploration company. It owns and operates the silver, gold, zinc, and lead Cordero project. The company was formerly known as 1027949 B.C. Ltd. and changed its name to Levon Resources Ltd. in July 2015. Levon Resources Ltd. was founded in 2015 and is headquartered in Vancouver, Canada.

Founded in 2015

scivac therapeutics inc (LO9) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

scivac therapeutics inc (LO9) Key Developments

Levon Resources Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Levon Resources Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net loss for the period was CAD 2,169,465 or CAD 0.01 basic and diluted loss per share against CAD 1,187,068 or CAD 0.01 basic and diluted loss per share a year ago. Net loss before income taxes was CAD 1,897,364 against CAD 1,187,068 a year ago. Interest income Was CAD 152,971 compared to CAD 160,959 for the same period last year. Cash used in operating activities was CAD 692,909 against CAD 839,170 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LO9:GR €0.18 EUR +0.018

LO9 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LO9.
View Industry Companies
 

Industry Analysis

LO9

Industry Average

Valuation LO9 Industry Range
No financial data is available for LO9.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCIVAC THERAPEUTICS INC, please visit www.levon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.